GlassScriptPhysician profile
Erika Connor
NPI 1336136274
$6,085.33
in general payments reported to CMS, 2019-2025
41 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $842 · 2021: $1,161 · 2022: $1,117 · 2023: $903 · 2024: $669 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.27 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,033.45 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $926.89 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $564.72 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $392.68 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $301.24 | 2020-2023 | Seglentis, Livalo |
| Amgen INC. | $286.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $266.07 | 2020-2023 | Viberzi, Linzess, Ubrelvy |
| Pfizer INC. | $235.19 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.58 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $176.14 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $143.11 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| Grifols USA, LLC | $139.78 | 2020-2024 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $132.21 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.00 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $97.81 | 2021-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.